目的：系统评价罗替戈汀透皮贴剂治疗帕金森病（PD）的有效性和安全性。方法：计算机检索中国期 刊全文数据库（CNKI）、万方学术期刊全文数据库（Wanfang）、维普中文科技期刊数据库（VIP）、中国生物医 学文献数据库（Sino Med）、PubMed、Cochrane图书馆（Cochrane Library）、Embase数据库等7个数据库，搜集 罗替戈汀透皮贴剂治疗PD的临床随机对照试验，检索时限均为建库至2020年11月11日。由两位研究者独 立对文献进行资料提取和质量评价后，使用Stata软件和RevMan软件进行Meta分析。结果：共纳入16项 RCT 研究，包括 4 682 例受试者。Meta 分析结果显示罗替戈汀透皮贴剂显著降低 PD 患者的 UPDRS-Ⅲ、 UPDRS-Ⅱ及UPDRS-(Ⅱ+Ⅲ)评分，改善了PD患者的运动症状和日常生活症状；此外，罗替戈汀透皮贴剂显 著降低了PD患者的PDSS-2评分，改善了PD患者的睡眠质量。与安慰剂对照组相比，罗替戈汀透皮贴剂并 未增加不良事件的发生率。结论：证实罗替戈汀透皮贴剂治疗PD的有效性和安全性。

To assess the efficacy and safety of Rotigotine transdermal patch (TP) in patients with Parkinson’s disease (PD). Methods: Articles were searched for involving randomized controlled trials (RCTs) of PD treatment using rotigotine TP that were published before November 11, 2020 on the CNKI, Wangfang, VIP, Sino Med, PubMed, Cochrane Library, and EMBASE databases. Data extraction and assessment of methodological bias of the RCTs were independently completed by 2 researchers. Meta-analysis of data was performed using Stata and RevMan software. Results: A total of 16 RCTs with 4 682 PD patients were enrolled. Rotigotine TP significantly reduced UPDRS-Ⅲ, UPDRS-Ⅱ, and UPDRS-(Ⅱ+Ⅲ) scores, indicating that the treatment led to a significant amelioration of movement symptoms and ADL limitations. Moreover, Rotigotine TP significantly reduced PDSS-2 scores, suggesting that it led to a remarkable improvement in sleep quality. Compared with placebo group subjects, patients taking Rotigotine TP did not experience a greater incidence of adverse events. Conclusion: The efficacy and safety of Rotigotine TP in treating PD were verified.